HomeALTME • EPA
add
TME Pharma NV
Previous close
€0.057
Day range
€0.054 - €0.065
Year range
€0.049 - €0.15
Market cap
5.62M EUR
Avg Volume
359.72K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 13.50K | — |
Operating expense | 982.00K | -28.24% |
Net income | -1.05M | 35.28% |
Net profit margin | -7.79K | — |
Earnings per share | — | — |
EBITDA | -965.00K | 27.74% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.06M | -23.79% |
Total assets | 2.29M | -22.06% |
Total liabilities | 2.86M | 108.22% |
Total equity | -570.00K | — |
Shares outstanding | 94.09M | — |
Price to book | -5.65 | — |
Return on assets | -105.59% | — |
Return on capital | -210.54% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -1.05M | 35.28% |
Cash from operations | -1.43M | -4.57% |
Cash from investing | 4.00K | 200.00% |
Cash from financing | 836.00K | -47.78% |
Net change in cash | -590.00K | -357.64% |
Free cash flow | -555.00K | 23.25% |
About
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Founded
1997
Website
Employees
12
